Please wait a minute...
Reviews in Cardiovascular Medicine  2014, Vol. 15 Issue (1): 52-62     DOI: 10.3909/ricm0710
Review Previous articles | Next articles
L-carnitine for the Treatment of Acute Myocardial Infarction
James J. DiNicolantonio1, 2, Asfandyar K. Niazi3, Mark F. McCarty4, Carl J. Lavie5, 6, Evangelos Liberopoulos7, James H. O'Keefe1
1 Mid America Heart Institute at Saint Luke's Hospital, Kansas City, MO
3 Shifa College of Medicine, Islamabad, Pakistan
4 NutriGuard Research, Inc, Encinitas, CA
5 John Ochsner Heart and Vascular Institute, Ochsner Clinical School, the University of Queensland School of Medicine, New Orleans, LA
6 Pennington Biomedical Research Center, Baton Rouge, LA
7 Department of Internal Medicine, University of Ioannina Medical School, Ioannina, Greece
Download:  PDF(275KB)  ( 97 )
Export:  BibTeX | EndNote (RIS)      
Although the therapeutic strategies available for treating acute myocardial infarction (AMI) have evolved dramatically in recent decades, coronary artery disease remains the leading cause of death in our society, and the rates of recurrent myocardial infarction and mortality are still unacceptably high. Therefore, exploration of alternative therapeutic strategies for AMI is of utmost importance. One such strategy is to target metabolic pathways via L-carnitine supplementation. L-carnitine is a physiologically essential metabolic cofactor that has been shown to provide a plethora of benefits when administered after AMI. L-carnitine has been shown to lessen infarct size, to reduce ventricular arrhythmias, left ventricular dilation, and heart failure incidence, as well as improve survival. These benefits may, in part, be related to its ability to boost glucose oxidation in is chemic tissues, while moderating increases in fatty acyl-coenzyme A levels that can impair mitochondrial efficiency and promote oxidative stress and inflammation. This article summarizes the evidence pertinent to the therapeutic use of L-carnitine for AMI.
Key words:  L-carnitine      Acute myocardial infarction      Ischemia      Mitochondria      Fatty acids     
Published:  30 March 2014     

Cite this article: 

James J. DiNicolantonio, Asfandyar K. Niazi, Mark F. McCarty, Carl J. Lavie, Evangelos Liberopoulos, James H. O'Keefe. L-carnitine for the Treatment of Acute Myocardial Infarction. Reviews in Cardiovascular Medicine, 2014, 15(1): 52-62.

URL:     OR

[1] En Chen, Wei Cai, Danqing Hu, Lianglong Chen. Effect of remote ischemic preconditioning in patients with STEMI during primary percutaneous coronary intervention: a meta-analysis of randomized controlled trials[J]. Reviews in Cardiovascular Medicine, 2020, 21(1): 103-112.
[2] Zheng Wang, Zhan Wang, Tiezhong Wang, Jiayang Yuan, Xuechen Wang, Zhiguo Zhang. Inhibition of miR-34a-5p protected myocardial ischemia reperfusion injury-induced apoptosis and reactive oxygen species accumulation through regulation of Notch Receptor 1 signaling[J]. Reviews in Cardiovascular Medicine, 2019, 20(3): 187-197.
[3] Adriana D. Adameova, Sukhwinder K. Bhullar, Vijayan Elimban, Naranjan S. Dhalla. Activation of β1-adrenoceptors may not be involved in arrhythmogenesis in ischemic heart disease[J]. Reviews in Cardiovascular Medicine, 2018, 19(3): 97-101.
[4] Emily Tat, Richard Cheng, Jeffrey S. Helfenstein. Forty Years of Chest Pain: A Case Report and Contemporary Review of the Diagnostic and Therapeutic Options for Myocardial Bridging[J]. Reviews in Cardiovascular Medicine, 2016, 17(1-2): 69-75.
[5] Ibrahim Sidiqi, Patrick Alexander. Current Advances in Endovascular Therapy for Infrapopliteal Artery Disease[J]. Reviews in Cardiovascular Medicine, 2015, 16(1): 36-50.
[6] Olayinka Afolabi-Brown, D. Lynn Morris, Vincent M. Figueredo. Global T-wave Inversion on Electrocardiogram: What Is the Differential?[J]. Reviews in Cardiovascular Medicine, 2014, 15(2): 131-141.
[7] Subrata Kar. Role of Omega-3 Fatty Acids in the Prevention of Atrial Fibrillation[J]. Reviews in Cardiovascular Medicine, 2013, 14(2-4): 82-91.
[8] Sophie Mavrogeni, Fabrizio Cantini, Gerald M. Pohost. Systemic Vasculitis: An Underestimated Cause of Heart Failure—Assessment by Cardiovascular Magnetic Resonance[J]. Reviews in Cardiovascular Medicine, 2013, 14(1): 49-55.
[9] Adam C. Salisbury, Mikhail Kosiborod. Hospital-Acquired Anemia in Patients With Cardiovascular Disease: Incidence, Outcomes, and Opportunities for Prevention[J]. Reviews in Cardiovascular Medicine, 2012, 13(4): 150-160.
[10] Kasia J. Lipska, Mikhail Kosiborod. Management of Blood Glucose in Patients With Acute Coronary Syndromes[J]. Reviews in Cardiovascular Medicine, 2012, 13(2-3): 77-88.
[11] Kanwal Pratap Singh Raghav, Premraj Makkuni, Vincent M. Figueredo. A Review of Electrocardiography in Pulmonary Embolism: Recognizing Pulmonary Embolus Masquerading as ST-Elevation Myocardial Infarction[J]. Reviews in Cardiovascular Medicine, 2011, 12(3): 157-163.
[12] Victor Marinescu, Karolina K. Mirowska, Theodore Schreiber, Mahir Elder, Mircea Petrina. Insights Into Endovascular Revascularization in Limb Salvage Procedures: "Antegrade-Retrograde" Technique in Chronic Total Occlusion[J]. Reviews in Cardiovascular Medicine, 2011, 12(1): 42-47.
[13] Peter A. McCullough. Integration of the Clinical Laboratory in Cardiovascular Medicine[J]. Reviews in Cardiovascular Medicine, 2010, 11(S2): 1-2.
[14] Peter A. McCullough, W. Frank Peacock, Brian O'Neil, James A. de Lemos. Capturing the Pathophysiology of Acute Coronary Syndromes With Circulating Biomarkers[J]. Reviews in Cardiovascular Medicine, 2010, 11(S2): 3-12.
[15] Peter A. McCullough, W. Frank Peacock, Brian O'Neil, James A. de Lemos, Norman E. Lepor, Robert Berkowitz. An Evidence-Based Algorithm for the Use of B-Type Natriuretic Testing in Acute Coronary Syndromes[J]. Reviews in Cardiovascular Medicine, 2010, 11(S2): 51-65.
No Suggested Reading articles found!